{
  "docId": "019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "docSlug": "78e7004510e3b27003e9c94a6172e682",
  "documentTitle": "Chimerix | Investor Presentation Deck | 38 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 38,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide details specific inclusion/exclusion criteria including age, mutation status, disease progression, prior therapy, and washout periods.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-80bf-72b8-b7b1-d0f771f9e60f/8",
  "deckHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "deckJsonHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f.json",
  "deckAnchorHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.19
      },
      "kind": "list",
      "text": "Objective: To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2306bc21-0775-4c8c-8879-d950eaa39e0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.94,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "list",
      "text": "Eligibility: Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018; Diffuse glioma with a known H3 K27M mutation; Progressive and measurable disease; Prior therapy; Washout periods; Performance status; Corticosteroids; Exclusions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0578647-fd97-4402-82a9-8764e07d1ede",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "FDA-aligned criteria for Phase 2 efficacy analysis to isolate ONC201 single agent activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "331ad7ff-0b67-4391-9e3e-f7d21680228f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-protocol",
      "slug": null,
      "matchId": "37c45130-4b53-4844-8b84-7222bb1a6e2e",
      "evidence": "Structured presentation of study objective and patient eligibility criteria.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}